Chronic Hepatitis B Virus
Chronic Hepatitis B Virus Market

Hepatitis B is a life-threatening disease caused by the Hepatitis B Virus (HBV), which attacks and injures the liver. If an individual suffers from an HBV infection that lasts more than six months, it becomes chronic. 


Chronic Hepatitis B Virus Epidemiological Segmentation

The Epidemiological Segmentation of Chronic Hepatitis B Virus in 7MM from 2017 to 2030 is segmented as:-

  • Total Prevalent Cases of Chronic Hepatitis B Virus
  • Total Diagnosed Prevalent Cases Chronic Hepatitis B Virus
  • Gender-Specific Cases of Chronic Hepatitis B Virus
  • Age-Specific Cases Cases of Chronic Hepatitis B Virus
  • Chronic Hepatitis B Virus cases by Impact on Liver (decompensated and compensated)
  •  Treated Cases Cases of Chronic Hepatitis B Virus


Chronic Hepatitis B Virus Epidemiology (2017)

  • The total incident population of Chronic Hepatitis B Virus in 7MM was 5,797,240.
  • Age-specific Chronic Hepatitis B Virus Cases are:-
  • 48,774 - <18 years
  • 417,880 - 18–34 years
  • 385,462 - 35–44 years
  • 410,357 - 45–54 years
  • 294,578 - 55–64 years
  • 75,479 - ≥65 years 
  • The total number of Chronic Hepatitis B Virus prevalent cases in the United States was found to be 2,276,030.
  • The total Chronic Hepatitis B Virus prevalent cases in Germany were 564,158.
  • In Japan, the total number of Chronic Hepatitis B Virus prevalent cases was observed to be 1,289,804.
  • The total number of Chronic Hepatitis B Virus cases in Spain was estimated to be 342,707.

 

Chronic Hepatitis B Virus Market

The therapeutic market size of the Chronic Hepatitis B Virus in 7MM in 2017 was USD 1,657 million.

 

Chronic Hepatitis B Virus Market Drivers

  • Increase in prevalent pool owing to rising awareness and WHO initiatives
  • Advancement in vaccine technology and novel therapeutic agents 


Chronic Hepatitis B Virus Market Barriers

  • Limited access to medical care and diagnostic tools
  • Availability of generics and anticipated higher usage of generics in the near future 


Chronic Hepatitis B Virus Emerging Drugs

The emerging drugs of the Chronic Hepatitis B Virus market are:

  • GSK3228836 (IONIS-HBVRx)
  • GSK3389404 (IONIS-HBV-LRX)
  • ABI-H2158
  • Vebicorvir
  • JNJ-56136379 (JNJ-6379)
  • Sci-B-Vac
  • Vesatolimod (GS-9620)
  • GS-9688 (Selgantolimod)
  • RG7854 and RG7907 combination
  • JNJ-73763989 and/or JNJ-56136379
  • Cemiplimab

And several others.


Chronic Hepatitis B Virus Key Players

The key players in the Chronic Hepatitis B Virus market are:

  • GlaxoSmithKline/Ionis Pharma
  • GlaxoSmithKline /Ionis Pharmaceuticals
  • Assembly Biosciences
  • Assembly Biosciences
  • Janssen Sciences Ireland
  • VBI Vaccines
  • Gilead Sciences
  • Gilead Sciences
  • Roche
  • Janssen/Arrowhead Pharmaceuticals
  • Regeneron Pharmaceuticals

 And several others.